Tempest Therapeutics (NASDAQ:TPST) Receives “Buy” Rating from HC Wainwright

Tempest Therapeutics (NASDAQ:TPST)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $47.00 price target on the stock.

Tempest Therapeutics Stock Performance

Shares of Tempest Therapeutics stock opened at $1.08 on Wednesday. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.12. The stock’s fifty day moving average is $1.21 and its two-hundred day moving average is $1.98. Tempest Therapeutics has a 52 week low of $0.86 and a 52 week high of $6.00. The company has a market capitalization of $27.23 million, a PE ratio of -0.67 and a beta of -1.78.

Institutional Investors Weigh In On Tempest Therapeutics

Several large investors have recently added to or reduced their stakes in TPST. Empower Advisory Group LLC bought a new stake in shares of Tempest Therapeutics during the third quarter valued at approximately $49,000. Fullcircle Wealth LLC bought a new stake in Tempest Therapeutics during the 3rd quarter valued at $87,000. Dimensional Fund Advisors LP purchased a new stake in shares of Tempest Therapeutics in the 2nd quarter worth $55,000. Finally, Virtu Financial LLC grew its position in shares of Tempest Therapeutics by 69.2% during the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock worth $112,000 after buying an additional 11,689 shares in the last quarter. 22.52% of the stock is owned by hedge funds and other institutional investors.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.